Business Context and Reporting Period
Company: Dermata Therapeutics, Inc. (DRMA)
Filing Type: Form 8-K (Current Report)
Report Date: March 26, 2026
Reporting Period: Fiscal Year Ended December 31, 2025
Context: The filing serves to disclose the Company's results of operations for the fiscal year 2025 via a press release furnished as Exhibit 99.1. The Company is an emerging growth company.
Key Financial Metrics
The provided Form 8-K text acts as a cover document referencing a press release (Exhibit 99.1) for detailed financial data. The filing text itself does not contain specific numerical values for the following metrics:
- Revenue: Not provided in filing text.
- Profit/Loss: Not provided in filing text.
- Cash Flow: Not provided in filing text.
- Margins: Not provided in filing text.
- Debt and Liquidity: Not provided in filing text.
Material Changes
The filing text does not provide specific comparative data or details regarding material changes versus the prior comparable period. Investors must refer to the attached press release (Exhibit 99.1) for year-over-year analysis.
Guidance, Outlook, and Risks
Management Commentary: The filing references a "Corporate Update" and financial results report issued on March 26, 2026, but does not include the text of the commentary, guidance, or outlook within this document.
Risks and Contingencies: No specific risks or contingencies are detailed in the Form 8-K text provided.
Unusual Items: None identified in the filing text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 26, 2026) for actual revenue, net loss, and cash position figures for the year ended December 31, 2025.
- Verify the Company's cash runway and burn rate as disclosed in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the "Corporate Update."
- Confirm the status of the Company's emerging growth company election and any related accounting standard transitions.